An error in a Phase IIb trial for Cytokinetics' (CYTK) Tirasemtiv treatment for Lou Gehrig's...
An error in a Phase IIb trial for Cytokinetics' (CYTK) Tirasemtiv treatment for Lou Gehrig's disease caused 58 patients who initially received the drug to later receive a placebo. So far 50 patients have been enrolled in the trial. Cytokinetics now has to decide whether to raise the number of patients in the study, which could increase its costs and delay the results. Shares are about to resume trading after being halted.
From other sites
at CNBC.com (Jul 1, 2013)
at CNBC.com (Jun 26, 2013)
at CNBC.com (Jun 25, 2013)
at CNBC.com (May 10, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs